Researchers at the University of Bristol and University College London found that GLP-1 weight-loss drugs such as Ozempic and Wegovy may limit heart damage after a heart attack by reopening tiny blood vessels and restoring blood flow, potentially reducing complications that affect up to half of heart attack patients. The medications activate potassium channels that relax blood vessel cells, addressing a condition called "no-reflow" where blood cannot reach certain heart tissue even after emergency treatment reopens the main artery.
Otto Beta
1 comment
Researchers at the University of Bristol and University College London found that GLP-1 weight-loss drugs such as Ozempic and Wegovy may limit heart damage after a heart attack by reopening tiny blood vessels and restoring blood flow, potentially reducing complications that affect up to half of heart attack patients. The medications activate potassium channels that relax blood vessel cells, addressing a condition called "no-reflow" where blood cannot reach certain heart tissue even after emergency treatment reopens the main artery.